导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.69% | 2385/4773 |
| 近一周 | -2.30% | 1720/5462 |
| 近一月 | -4.51% | 2525/5421 |
| 近一季 | -7.34% | 2367/5209 |
| 近半年 | -3.64% | 2272/4920 |
| 近一年 | 2.67% | 2070/4366 |
| 近两年 | 49.55% | 1475/2954 |
| 近三年 | 30.33% | 1046/2253 |
| 成立以来 | 46.83% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.39% 2772/4961 |
13.63% 1978/5312 |
- - |
- - |
| 2025 | 21.67% 2022/4813 |
-0.17% 2090/3635 |
1.70% 2221/4076 |
18.81% 2244/4524 |
0.86% 1708/4813 |
| 2024 | 15.17% 958/3463 |
2.41% 781/2808 |
-1.72% 1099/3014 |
16.83% 1341/3129 |
-2.06% 1941/3463 |
| 2023 | -8.62% 1034/2656 |
5.17% 819/2280 |
-4.35% 1147/2385 |
-3.40% 921/2515 |
-5.96% 1572/2655 |
| 2022 | -18.60% 733/2207 |
-13.72% 824/1919 |
6.06% 776/2016 |
-12.83% 793/2113 |
2.04% 1059/2208 |
| 2021 | 1.72% 656/1822 |
-2.36% 628/1255 |
6.13% 765/1330 |
-3.48% 641/1466 |
1.70% 834/1822 |
| 2020 | 35.86% 408/1250 |
-6.49% 488/1028 |
16.37% 443/1067 |
12.51% 381/1164 |
10.97% 573/1184 |
| 2019 | 39.34% 284/1092 |
28.74% 298/739 |
-1.58% 311/788 |
1.39% 407/850 |
8.46% 315/918 |
| 2018 | -23.72% 295/834 |
- - |
-8.98% 258/631 |
-2.40% 285/660 |
-11.47% 297/682 |
| 2017 | 17.46% 226/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.74% 308/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证800指数C VS. 长安沪深300非周期A(740101) |